Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Pulvinar sapien et ligula ullamcorper malesuada. Porta nibh venenatis cras sed felis eget velit aliquet sagittis. Ultrices eros in cursus turpis. Eleifend mi in nulla posuere sollicitudin aliquam. Commodo ullamcorper a lacus vestibulum sed arcu non. Quis enim lobortis scelerisque fermentum dui faucibus in ornare. Id cursus metus aliquam eleifend mi in nulla posuere sollicitudin. Gravida in fermentum et sollicitudin ac orci phasellus egestas. Commodo ullamcorper a lacus vestibulum sed arcu non odio. Urna molestie at elementum eu facilisis sed. Quam viverra orci sagittis eu volutpat odio facilisis. Arcu dui vivamus arcu felis bibendum ut tristique. Ac orci phasellus egestas tellus rutrum. Mauris vitae ultricies leo integer malesuada nunc. Diam ut venenatis tellus in metus vulputate eu scelerisque. Nisl nisi scelerisque eu ultrices. Sit amet nisl purus in mollis nunc sed id.
Welcome to the first OPACE newsletter! Many thanks to you all for your hard work and support in this trial. SITES UPDATE We currently have 12 research sites active for OPACE, which include: Primary Care Sites Secondary Care Sites · Heath Lane Surgery · Vauxhall Primary Health Care · Knutsford Medical Partnership · […]
As of 26th Sep 2023, we are pleased to confirm final approvals have been received from the Medicines and Healthcare products Regulatory Agency (MHRA), the Research Ethics Committee (REC), and Health Research Authority (HRA) for the OPACE trial to proceed. What happens next? Following approvals, we can start initiating and activating sites to begin […]